Study on the luminescence behavior of sulfobutylether-β-cyclodextrin with risperidone and its analytical application

The interaction of sulfobutylether-β-cyclodextrin (SBE-β-CD) with risperidone (RISP) was first described with luminol–SBE-β-CD chemiluminescence (CL) system by flow injection analysis (FIA). In luminol–SBE-β-CD CL system, the 1:1 SBE-β-CD⋯luminol∗ complexation could enhance CL intensity of luminol and produce the effect of complexation enhancement of CL (CEC). It was found that RISP could quench the CL intensity of SBE-β-CD⋯luminol∗ and caused the effect of complexation enhancement of quenching (CEQ), the formation constant KR-CD 3.4 × 104 L mol−1 and the stoichiometric ratio 1:1 of RISP⋯SBE-β-CD complex were obtained by the proposed CL model. Association degree α 0.036 of RISP⋯SBE-β-CD complex was also given by CL method. Based on the linear relationship to the decrement of luminol–SBE-β-CD–RISP CL intensity and the logarithm of RISP concentration, RISP also can be quantified in the linear range of 3.0–500.0 nmol L−1 with a detection limit of 1.0 nmol L−1 (3σ). The proposed method was successfully applied to monitoring excreted RISP in human urine. It was found that RISP reached its maximum after oral administration for 1.5 h with the total excretion of 14.26% within 8.5 h; the elimination rate constant k and half-life time t1/2 were 0.474 and 1.5 h, respectively.

Figure optionsDownload as PowerPoint slideHighlights
► The first time describes the linear quenching of RISP to luminol/SBE-β-CD CL system.
► The possible mechanism of luminol/SBE-β-CD/RISP reaction with the proposed model.
► This method offers a higher sensitivity and wider linear range for assaying RISP.